SARS-CoV-2 spike glycoprotein non-receptor binding domain epitope (SARS-CoV-2 S non-RBD epitopes)

The SARS-CoV-2 spike glycoprotein non-receptor binding domain (non-RBD) epitopes encompass antigenic regions on the spike protein that are distinct from the primary receptor-binding domain (RBD). These epitopes are primarily located within the N-terminal domain (NTD) of the S1 subunit and the highly conserved S2 subunit, which includes the fusion peptide and heptad repeat regions (Walls et al., 2020, Cell). While the RBD is the most common target for neutralizing antibodies, non-RBD epitopes play essential roles in viral attachment and the complex conformational changes required for membrane fusion (Chi et al., 2020, Science). Antibodies targeting the NTD can inhibit viral entry by interfering with auxiliary receptor interactions or preventing spike transitions, while S2-targeting antibodies often exhibit broad-spectrum activity across different betacoronaviruses due to high sequence conservation (Pinto et al., 2020, Nature). These regions are critical therapeutic targets because they are often less prone to the rapid mutational escape seen in the RBD, making them ideal for developing variant-proof vaccines and monoclonal therapies (Ng et al., 2020, Science). Understanding these epitopes is vital for monitoring immune evasion and enhancing the breadth of the human immune response against SARS-CoV-2 and its emerging variants (Harvey et al., 2021, Nature Reviews Microbiology).

Other names

N-terminal domain (NTD) epitopesS2 subunit epitopesSpike protein stem regionFusion peptide epitopesHeptad repeat 1 (HR1) epitopesHeptad repeat 2 (HR2) epitopesSARS-CoV-2 S1-NTDSARS-CoV-2 S2 fusion machinery

Neutralization of viral infection by blocking membrane fusion, inhibiting conformational changes, or preventing viral attachment to host cells.